Sertraline and Tirzepatide Concurrent Use
Concurrent use is generally considered safe based on the absence of a specific, labeled drug–drug interaction between sertraline and tirzepatide. [1], [2] Tirzepatide is labeled to delay gastric emptying and to potentially affect the absorption of concomitantly administered oral medications, so absorption of oral sertraline may be delayed without a specific, clinically established interaction described in labeling. [1], [3]
Drug Interaction Mechanism Relevant to Oral Absorption
Tirzepatide delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. [1] This mechanism is clinically relevant primarily for oral drugs where efficacy depends on timely or adequate absorption. [1], [3]
Sertraline Metabolism and Drug–Drug Interaction Profile
Sertraline has labeled drug interaction considerations primarily involving CYP2D6 inhibition and specific co-medications. [2] The sertraline label does not identify tirzepatide as a drug that changes sertraline exposure. [2]
Evidence From Tirzepatide Labeling
MOUNJARO (tirzepatide) labeling advises caution with concomitant oral medications due to delayed gastric emptying. [1] Tirzepatide labeling specifically recommends monitoring oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index, such as warfarin. [1] Sertraline is not called out in tirzepatide labeling among examples requiring therapeutic drug monitoring. [1]
Practical Coadministration Considerations
Sertraline can be continued when tirzepatide is initiated or doses are escalated, with attention to antidepressant tolerability and clinical response. [1], [2] If gastrointestinal adverse effects occur with tirzepatide, tolerability of oral sertraline may be affected indirectly through nausea or vomiting. [1], [3]
Situations Requiring Additional Monitoring
Additional monitoring is recommended for oral medications dependent on threshold concentrations for efficacy when used with tirzepatide. [1] In settings requiring precise oral exposure, assessment of antidepressant clinical response after tirzepatide initiation or dose escalation supports safety monitoring because gastric emptying delay can alter absorption kinetics. [1], [3]
Safety Summary
No specific interaction between sertraline and tirzepatide is described in labeling, so concurrent use is generally compatible. [1], [2] Tirzepatide’s delayed gastric emptying effect creates a general need for caution with concomitant oral medications, which supports monitoring of clinical response to sertraline after initiation and during dose escalation. [1], [3]